These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32990050)

  • 1. Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients.
    Giraud EL; Jessurun NT; van Hunsel FPAM; van Puijenbroek EP; van Tubergen A; Ten Klooster PM; Vonkeman HE
    Expert Opin Drug Saf; 2020 Dec; 19(12):1617-1624. PubMed ID: 32990050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995-2015).
    Almutairi KB; Inderjeeth CA; Preen DB; Keen HI; Nossent JC
    Rheumatol Int; 2024 Jun; 44(6):1089-1099. PubMed ID: 38615313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry.
    Giraud EL; Thomas PWA; van Lint JA; van Puijenbroek EP; Römkens TEH; West RL; Russel MGVM; Jansen JM; Jessurun NT; Hoentjen F;
    Drug Saf; 2021 May; 44(5):581-588. PubMed ID: 33538994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Machado-Alba JE; Ruiz AF; Machado-Duque ME
    Rev Panam Salud Publica; 2014 Dec; 36(6):396-401. PubMed ID: 25711751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
    Mittal N; Sharma A; Jose V; Mittal R; Wanchu A; Bambery P
    Rheumatol Int; 2012 Mar; 32(3):743-8. PubMed ID: 21161534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions.
    Abasolo L; Leon L; Rodriguez-Rodriguez L; Tobias A; Rosales Z; Maria Leal J; Castaño V; Vadillo C; Macarron P; Fontsere O; Jover JA
    Semin Arthritis Rheum; 2015 Apr; 44(5):506-513. PubMed ID: 25532946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.
    Cho SK; Sakai R; Nanki T; Koike R; Watanabe K; Yamazaki H; Nagasawa H; Tanaka Y; Nakajima A; Yasuda S; Ihata A; Ezawa K; Won S; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Miyasaka N; Bae SC; Harigai M; ;
    Mod Rheumatol; 2014 Jul; 24(4):572-9. PubMed ID: 24320747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of novel drug-adverse drug reaction signals in rheumatoid arthritis and ankylosing spondylitis: analysis of Korean real-world biologics registry data.
    Kwon M; Joung CI; Shin H; Lee CC; Song YS; Lee YJ; Kang S; Kim JY; Lee S
    Sci Rep; 2024 Feb; 14(1):2660. PubMed ID: 38302579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
    Velthuis K; Jessurun NT; Nguyen TDM; Scholl J; Jansen JRG; van Lint JA; Kosse LJ; Ten Klooster PM; Vonkeman HE
    Expert Opin Drug Saf; 2023; 22(6):485-492. PubMed ID: 36683590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [DMARDs (disease-modifying antirheumatic drugs)].
    Tanaka E; Yamanaka H
    Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
    Leon L; Gomez A; Vadillo C; Pato E; Rodriguez-Rodriguez L; Jover JA; Abasolo L
    Clin Exp Rheumatol; 2018; 36(1):29-35. PubMed ID: 28598787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.
    Blomqvist P; Feltelius N; Ekbom A; Klareskog L
    J Rheumatol; 2000 May; 27(5):1171-7. PubMed ID: 10813283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
    Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan.
    Takeuchi T; Ishida K; Shiraki K; Yoshiyasu T
    Mod Rheumatol; 2018 Jan; 28(1):48-57. PubMed ID: 28649878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
    Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
    Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.